Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/07853890.2014.991751 http://scihub22266oqcxt.onion/10.3109/07853890.2014.991751 C4638420!4638420!25613169     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Med 2015 ; 47 (2): 100-5 Nephropedia Template TP {{tp|p=25613169|t=2015. Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Future |pdf=|usr=}}{{25613169}} gab.com Text Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Future JO: Ann Med http://www.kidney.de/pget.php?&tw=1&pmid=25613169 #FOAvip Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiology that affects approximately 150,000 patients in the United States. It carries a median survival of two to three years, but clinical course can vary markedly from patient to patient. There has been no established treatment for IPF, but recent advances in coordinated clinical trials through groups such as IPFnet and academia-industry partnerships have allowed this relatively rare disease to be studied in much greater depth. Historically, the default therapy for IPF was a combination of prednisone, N-acetylcysteine, and azathioprine, but recent trials have shown that this regimen actually increases mortality. An enormous body of work in recent years, spanning the bench to the bedside, has radically altered our understanding of the molecular mechanisms underlying IPF. Newer modalities, particularly those involving monoclonal antibodies targeted at specific pathways known to contribute to the fibrotic process, have generated a great deal of excitement in the field, and recent clinical trials on therapies such as pirfenidone and nintedanib herald a new era in targeted IPF therapies. Twit Text FOAVip Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Future ????Ann Med http://www.kidney.de/pget.php?&tw=1&pmid=25613169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25613169 #FOAvip English Wikipedia <ref>{{Cite pmid|25613169}}</ref> Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Future #MMPMID25613169 Staitieh BS; Renzoni EA; Veeraraghavan S Ann Med 2015[Mar]; 47 (2): 100-5 PMID25613169show ga Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiology that affects approximately 150,000 patients in the United States. It carries a median survival of two to three years, but clinical course can vary markedly from patient to patient. There has been no established treatment for IPF, but recent advances in coordinated clinical trials through groups such as IPFnet and academia-industry partnerships have allowed this relatively rare disease to be studied in much greater depth. Historically, the default therapy for IPF was a combination of prednisone, N-acetylcysteine, and azathioprine, but recent trials have shown that this regimen actually increases mortality. An enormous body of work in recent years, spanning the bench to the bedside, has radically altered our understanding of the molecular mechanisms underlying IPF. Newer modalities, particularly those involving monoclonal antibodies targeted at specific pathways known to contribute to the fibrotic process, have generated a great deal of excitement in the field, and recent clinical trials on therapies such as pirfenidone and nintedanib herald a new era in targeted IPF therapies. äPharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Fu(epmc).pdf DeepDyve Pubget Overpricing